Dr. Gary Steinberg

I mean, the patients and their families, it's changed their lives.

If you see them before and after, it's almost like a miracle.

Others are not as impressive, but so far in our trial, and we've treated 17 of the 18 intended patients,

Almost all the patients have recovered to some extent, and many of them have improved in a meaningful way if you use certain scales.

So again, we want to be cautious.

We're going to do a prospective randomized blinded controlled study, and that's the way it should be done.

And if that's positive, it would lead to a phase three larger study, again, blinded controlled.

And if that's positive, then it would lead to commercialization, FDA approval.

It's a long process.

I've spent 23 years and more than $46 million in grants and philanthropy getting it to this stage.

Wow.

Yeah.

Wow.

That's a lot of time and a lot of money.

That's the way science and translation to clinical medicine is?

No, but money is a factor.

It's not the only factor.

The FDA is appropriately very cautious.

I think other countries, the equivalent of the FDA moves things along a little quicker, especially for therapies where there's no other treatment.

So I think those factors are important and would accelerate it.